Evan Prescott Bailey - 19 Dec 2025 Form 4 Insider Report for Applied Therapeutics, Inc. (APLT)

Reporting relationship: Chief Medical Officer
Issuer ticker: APLT
Reported as of: 19 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2026, 18:46:19 UTC
Prior SEC filing: 17 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Leslie D. Funtleyder, as attorney-in-fact

Key filing fact

Evan Prescott Bailey filed Form 4 for Applied Therapeutics, Inc. (APLT) on 03 Feb 2026.

Key facts

This page summarizes Evan Prescott Bailey's Form 4 filing for Applied Therapeutics, Inc. (APLT).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Feb 2026, 18:46.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002071667 Primary reporting owner

Bailey Evan Prescott

Relationship: Chief Medical Officer
Address: C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK
Signature: /s/ Leslie D. Funtleyder, as attorney-in-fact
Signature date: 03 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLT transaction

Common Stock

Award

Transaction value: $0
Shares: +437,500
Change %: +51%
Price: $0.000000
Shares after: 1,296,816
Date: 19 Dec 2025
Ownership: Direct
Footnotes: F1, F2

APLT transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -1,235,915
Change %: -95%
Price
Shares after: 60,901
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F3, F4

APLT transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -60,901
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2026
Ownership: Direct
Footnotes: F3, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -19,531
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,531
Exercise price: $1.05
Footnotes: F6

APLT transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -4,883
Change %: -100%
Price
Shares after: 0
Date: 03 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,883
Exercise price: $1.05
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Evan Prescott Bailey is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.

Footnote F2

The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the understatement of the total holdings.

Footnote F3

Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").

Footnote F4

Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.

Footnote F5

Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

Footnote F6

Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.